Ketamine activates psychosis and alters limbic blood flow in schizophrenia
Neuroreport April 1, 1995 Adrienne C. Lahti, Henry H. Holcomb, Deborah R. Medoff et al. 440 citations
The non-competitive NMDA antagonist ketamine, given to schizophrenic individuals in subanesthetic doses, produced a short-lived, discrete activation of their psychotic symptoms, which had striking similarities to symptoms of their usual psychotic episodes. To further study this psychotomimetic property of ketamine, we administered 0.3 mg kg-1 of the drug to schizophrenic individuals during a...